Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

IRVINE, Calif., May 7, 2024 /PRNewswire/ — Seragon Biosciences, Inc. today announced the completion of a pre-clinical study on its novel anti-aging candidate, SRN-901. This pivotal study, conducted in mice, was undertaken to evaluate the impact of SRN-901 on aging as well as various…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks